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Flourine-18 fluoro-2-deoxy-glucose (18 F-FDG) positron emission tomography combined with computed tomography (PET/CT) is
a useful test for the management of malignant conditions. Inflammatory and infectious processes, however, can cause increased
uptake on PET scanning, often causing diagnostic dilemmas. This knowledge is important to the rheumatologist not only because
of the inflammatory conditions we treat but also because certain rheumatic diseases impose an increased risk of malignancy either
due to the disease itself or as a consequence of medications used to treat the rheumatic diseases. There is an increasing body of
evidence investigating the role of PET scans in inflammatory conditions. This paper describes a patient with rheumatoid arthritis
who developed pulmonary nodules that showed increased uptake on PET/CT scan and reviews the use of PET scanning in the
diagnosis and management of rheumatoid arthritis.

1. Introduction
Fluorine-18 fluoro-2-deoxyglucose (18 F-FDG) positron emission tomography combined with computed tomography
(PET/CT) is a useful test to evaluate malignancies [1]. However, inflammatory diseases may also show increased uptake
of 18 F-FDG and cause false-positive PET scan results, necessitating further investigations to rule out malignant conditions
[2]. Positron emission tomography (PET) is an analytical
imaging technology developed to use compounds labeled
with positron-emitting radioisotopes as molecular probes
to image and measure biochemical processes in vivo [3].
Numerous tracers have been used in conjunction with PET
scanning to aid in the diagnosis of various disorders. 18 FFDG has now become the most commonly used radiotracer
for PET scanning. Because of the increased metabolic activity
of the tumor cells, there is an increased uptake of glucose in
tumor cells, thus forming the basis for widespread use of 18 FFDG PET scan in the diagnosis, staging, and management
of malignancies. However, the increased uptake of 18 F-FDG

tracer is not limited to malignant states and has been seen in
benign as well as inflammatory conditions such as sarcoidosis, large vessel vasculitis, inflammatory bowel disease, and
rheumatoid arthritis (RA) [2, 4–8].
We describe a patient with RA who developed pulmonary
nodules, showing increased uptake on 18 F-FDG PET/CT
scan. We also review the current literature on the use of PET
scanning in articular and extra-articular RA.

2. Case Report
A 50-year-old Caucasian woman with a history of RA presented with dyspnea on exertion. RA was diagnosed 4 years
earlier and has been treated with methotrexate since the
time of diagnosis. RA is currently in remission on oral
methotrexate 15 mg weekly and folic acid 1 mg daily. Both
rheumatoid factor and anticitrullinated peptide antibody are
highly positive. Past medical history is significant for coronary artery disease with stent placement, chronic obstructive
pulmonary disease (COPD), hypothyroidism, hypertension,
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and gastroesophageal reflux disease. She has a 60-pack-year
smoking history and continues to smoke. Family history is
positive for a mother and sister with lung cancer who were
both heavy smokers and 2 sisters with COPD. She has lost 15–
20 pounds of weight intentionally over a period of 3 months.
There is history of loss of appetite. Physical examination
including joint examination is normal except for decreased
breath sounds in both upper lobes. Laboratory data revealed
normal blood count, erythrocyte sedimentation rate (ESR),
C-reactive protein (CRP), and renal and liver functions.
A chest X-ray done for evaluation of dyspnea on exertion
revealed a new right upper lobe (RUL) lung nodule. Her previous chest X-ray four years earlier showed multiple calcified
nodules bilaterally and a small noncalcified RUL nodule less
than a centimeter. CT chest revealed a 1.5 cm × 2.5 cm noncalcified pleural-based RUL nodule, a 1.1 cm calcified nodule in
the left upper lobe, and an 8 mm noncalcified nodule in the
right lower lobe (Figure 1). 18 F-FDG PET/CT scan showed
moderately increased uptake in all nodules with a maximum
standardized uptake value (SUV) of 3.7 in the RUL nodule
(Figure 2). Given the patient’s high risk based on tobacco
use and family history of lung cancer, she underwent a CTguided biopsy of the RUL nodule that was nondiagnostic.
Subsequent video-assisted thoracic surgery (VATS) biopsy
of the right upper and lower lobe nodules was performed.
Pathology of both nodules revealed chronic inflammation
with necrotizing granulomatous formation consistent with
rheumatoid nodules and no evidence of malignancy (Figures
3 and 4). Fungal and acid-fast bacilli stains and cultures were
negative.
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Figure 1: CT chest showing 1.5 cm × 2.5 cm RUL pleural-based nodule (arrow).

Figure 2: PET scan showing increased uptake in RUL nodule
(arrow).

3. Discussion
It has been noted that around 50 percent of solitary pulmonary nodules and a greater percentage of multiple pulmonary nodules turn out to be benign processes [9]. This,
in the face of 200,000 cases of lung cancer diagnosed per
year with mortality of 150,000 per year, creates a difficult
conundrum in the management of pulmonary nodules in diseases known to cause lung nodules such as RA [10]. 18 F-FDG
PET/CT scan has a sensitivity of 96-97% and a specificity
of 83–85% in differentiating malignant pulmonary nodules
[11–13]. However, the presence of inflammation and fibrosis
significantly hinders PET scan accuracy. This is compromised
even more so in the era of RA treatment with biologics that
confers increased risk of mycobacterial and fungal infections
which can potentially present as PET-positive lesions.
Reports of the use of PET and PET/CT in extra-articular
RA are limited to subcutaneous nodules, lymph nodes, and
the lung. Rodrı́guez et al. described two patients with RA
in whom pulmonary nodules showed increased SUV on
18
F-FDG PET scan [14]. Biopsy of the nodules demonstrated bronchogenic carcinoma developing within preexisting rheumatoid nodules. Based on their experience they concluded that PET scan is a diagnostic test of high accuracy and
can be used before surgical biopsy in patients with RA and
pulmonary nodules who are suspected to have bronchogenic
carcinoma. However, not all cases of increased uptake on
PET scan are related to malignancy as is evidenced by the

Figure 3: Mixed inflammatory infiltrate seen within the nodule.

Figure 4: Multinucleated giant cells with lymphocytes, fibroblasts,
and collagen in the granuloma wall.
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following reports. Gupta et al. described a patient with RA
found to have mild increased uptake in pulmonary nodules
on PET scan [15]. Histological examination of these nodules
revealed the presence of rheumatoid nodules. Bagga reported
a case of a 63-year-old female with severe RA and longstanding smoking history [16]. The patient had multiple pulmonary nodules and a left pleural effusion. PET scan showed
no uptake in the lung nodules but intense pleural uptake. A
CT-guided biopsy of both the nodules and the pleura was
performed, which confirmed the diagnosis of rheumatoid
lung disease. dos Anjos et al. reported a patient with RA in
whom increased 18 F-FDG uptake was found in subcutaneous
nodules and lymph nodes including cervical, supraclavicular,
axillary, and pelvic areas [17]. Similarly, Seldin et al. have
published a series of nine patients with RA having increased
FDG tracer uptake in the axillary lymph nodes [18]. Strobel
et al. described a patient with RA with a soft tissue nodule
on the left elbow [19]. Based on moderately increased activity
on PET scan, the patient underwent excision of the nodule. It
turned out to be a rheumatoid nodule.

4. Conclusion
The role of PET scan in diagnosis, staging, and management
of malignancies is well known. There is an increasing body of
evidence supporting the role of PET scans in nonmalignant
conditions including vasculitis and granulomatous diseases
such as sarcoidosis [20, 21]. The major factors limiting
widespread use of PET/CT scanning appear to be cost, availability, and radiation exposure. The role of PET scan in cases
of extra-articular involvement of RA has not been studied and
is limited to a very small number of case reports and case
series.
As evidenced by our case as well as other case reports,
increased activity on PET scan does not necessarily translate
into the diagnosis of malignancy. One would generally
assume that the degree of maximum FDG uptake is lower
in inflammatory lung nodules compared to malignancies.
However, this is not always the case, as RA nodules have
been reported with SUVs ranging from low to very high
[15, 16, 19, 22, 23]. Thus, SUV cannot be used to differentiate
between benign inflammatory and malignant lesions. Serial
monitoring with PET/CT scans may show a more stable SUV
uptake in benign inflammatory lesions compared to malignancies. Recently, the use of 11C-methionine PET scan has
been shown to be more sensitive in differentiating between
malignant and inflammatory lung lesions [24, 25]. 18 F-FDG
PET scan provides valuable information on joint involvement
as well as extra-articular disease in patients with RA. As
promising as PET scanning is for inflammatory joint conditions, larger studies are necessary, especially pertaining to
the cost effectiveness of routine PET scanning before its use
in clinical practice. Clinicians need to be aware of the fact
that rheumatoid nodules can have increased activity on PET
scan. With the increasing use of PET scan for evaluation of
lung nodules, rheumatologists will likely be confronted with
more such cases of increased PET uptake in RA patients.
Considering the lack of an established range of rheumatoid
nodule metabolic activity, close monitoring, with or without
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the use of invasive diagnostic methods such as needle biopsy
or VATS, is prudent in the management of lung nodules in
rheumatoid arthritis.
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